Nadine Gravius1,2, Shafqat R Chaudhry2,3, Sajjad Muhammad4, Azize Boström2,3, Sascha Gravius1,2, Thomas Randau1,2, Dirk Scheele2,5,6, Philipp Westhofen7, Johannes Kruppenbacher7, Birgit Stoffel-Wagner2,8, Christian Maier9, Anna Weidlich2,5,6, Thomas L Yearwood10, Krishnan V Chakravarthy11,12, Jeffery M Kramer13, Rene Hurlemann2,5,6, Thomas M Kinfe2,5,6. 1. Department of Orthopedics and Trauma Surgery, University Hospital Bonn, Bonn, Germany. 2. University Hospital Bonn, Rheinische Friedrich-Wilhelms-University Bonn, Bonn, Germany. 3. Department of Neurosurgery, University Hospital Bonn, Bonn, Germany. 4. Department of Neurosurgery, Helsinki University Hospital, Helsinki, Finland. 5. Department of Psychiatry, University Hospital Bonn, Bonn, Germany. 6. Division of Medical Psychology, University Hospital Bonn, Bonn, Germany. 7. Center for Hemostaseology and Transfusions Medicine, Bonn, Germany. 8. Department of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany. 9. Department of Radiology and Neuroradiology, Hochsauerland Clinics, Hospital Arnsberg, Arnsberg, Germany. 10. Comprehensive Pain and Rehabilitation, Daphne, AL, USA. 11. Department of Anesthesiology and Pain Medicine, University of California, San Diego Health Sciences, San Diego, CA, USA. 12. VA San Diego Healthcare System, San Diego, CA, USA. 13. Applied Research, Abbott, Sunnyvale, CA, USA.
Abstract
OBJECTIVES: Complex regional pain syndrome (CRPS) and associated comorbidities have been linked to a pro-inflammatory state driven by different mediators. Targeted dorsal root ganglion stimulation (DRGSTIM ) suppressed pain levels and improved functional capacity in intractable CRPS. However, clinical trials assessing the impact of DRG stimulation on the neuroimmune axis are lacking. METHODS: This study enrolled 24 subjects (12 refractory CRPS patients plus suitably matched healthy controls) and performed immunoassays of inflammatory mediators in saliva and serum along with score-based assessments of pain, mood, and sleep quality at baseline and after three months of selective L4-DRGSTIM . RESULTS: After three-month L4-DRGSTIM CRPS associated pain significantly decreased. In addition, disturbed sleep and mood improved post-DRGSTIM , although statistically not significant. Significantly increased serum values of pro-inflammatory markers were detected pre- and post L4-DRGSTIM for high-mobility group box 1, tumor-necrosis factor α, interleukin (IL) 6, and leptin. IL-1β was significantly elevated pre-L4 DRGSTIM , but not posttreatment. Elevated anti-inflammatory IL-10 significantly decreased after three months in serum, while saliva oxytocin concentrations increased in CRPS subjects after L4-DRGSTIM (p = 0.65). No severe implantation and stimulation associated adverse events were recorded. CONCLUSIONS: Selective L4-DRGSTIM improved neuropathic pain and functional impairment in CRPS as previously reported. CRPS patients displayed a pro-inflammatory molecular pattern in serum. Serum anti-inflammatory IL-10 significantly declined, while saliva oxytocin nonsignificantly increased after L4-DRGSTIM . An evidence-based relational interpretation of our study is limited due to the uncontrolled study design. However, molecular profiling of biofluids (saliva, serum) represents a novel and experimental field in applied neuromodulation, which warrant further investigations to unveil mechanisms of neuroimmune modulation.
OBJECTIVES: Complex regional pain syndrome (CRPS) and associated comorbidities have been linked to a pro-inflammatory state driven by different mediators. Targeted dorsal root ganglion stimulation (DRGSTIM ) suppressed pain levels and improved functional capacity in intractable CRPS. However, clinical trials assessing the impact of DRG stimulation on the neuroimmune axis are lacking. METHODS: This study enrolled 24 subjects (12 refractory CRPS patients plus suitably matched healthy controls) and performed immunoassays of inflammatory mediators in saliva and serum along with score-based assessments of pain, mood, and sleep quality at baseline and after three months of selective L4-DRGSTIM . RESULTS: After three-month L4-DRGSTIM CRPS associated pain significantly decreased. In addition, disturbed sleep and mood improved post-DRGSTIM , although statistically not significant. Significantly increased serum values of pro-inflammatory markers were detected pre- and post L4-DRGSTIM for high-mobility group box 1, tumor-necrosis factor α, interleukin (IL) 6, and leptin. IL-1β was significantly elevated pre-L4 DRGSTIM , but not posttreatment. Elevated anti-inflammatory IL-10 significantly decreased after three months in serum, while saliva oxytocin concentrations increased in CRPS subjects after L4-DRGSTIM (p = 0.65). No severe implantation and stimulation associated adverse events were recorded. CONCLUSIONS: Selective L4-DRGSTIM improved neuropathic pain and functional impairment in CRPS as previously reported. CRPS patients displayed a pro-inflammatory molecular pattern in serum. Serum anti-inflammatory IL-10 significantly declined, while saliva oxytocin nonsignificantly increased after L4-DRGSTIM . An evidence-based relational interpretation of our study is limited due to the uncontrolled study design. However, molecular profiling of biofluids (saliva, serum) represents a novel and experimental field in applied neuromodulation, which warrant further investigations to unveil mechanisms of neuroimmune modulation.
Authors: Martin Nüssel; Melanie Hamperl; Anna Maslarova; Shafqat R Chaudhry; Julia Köhn; Andreas Stadlbauer; Michael Buchfelder; Thomas Kinfe Journal: Pain Ther Date: 2020-12-16
Authors: Thomas M Kinfe; Maria Asif; Krishnan V Chakravarthy; Timothy R Deer; Jeffery M Kramer; Thomas L Yearwood; Rene Hurlemann; Muhammad Sajid Hussain; Susanne Motameny; Prerana Wagle; Peter Nürnberg; Sascha Gravius; Thomas Randau; Nadine Gravius; Shafqat R Chaudhry; Sajjad Muhammad Journal: J Transl Med Date: 2019-06-19 Impact factor: 5.531
Authors: Frank J P M Huygen; Jan Willem Kallewaard; Harold Nijhuis; Liong Liem; Jan Vesper; Marie E Fahey; Bram Blomme; Matthias H Morgalla; Timothy R Deer; Robyn A Capobianco Journal: Neuromodulation Date: 2019-11-15
Authors: Thomas M Kinfe; Michael Buchfelder; Shafqat R Chaudhry; Krishnan V Chakravarthy; Timothy R Deer; Marc Russo; Peter Georgius; Rene Hurlemann; Muhammad Rasheed; Sajjad Muhammad; Thomas L Yearwood Journal: Int J Mol Sci Date: 2019-09-24 Impact factor: 5.923
Authors: Ryan S D'Souza; Eva Kubrova; Yeng F Her; Ross A Barman; Brandon J Smith; Gabriel M Alvarez; Tyler E West; Alaa Abd-Elsayed Journal: Adv Ther Date: 2022-08-22 Impact factor: 4.070
Authors: Thomas Kinfe; Nico von Willebrand; Andreas Stadlbauer; Michael Buchfelder; Thomas L Yearwood; Sajjad Muhammad; Shafqat R Chaudhry; Sascha Gravius; Thomas Randau; Klemens Winder; Christian Maihöfner; Nadine Gravius; Walter Magerl Journal: J Transl Med Date: 2020-10-21 Impact factor: 5.531